Triphala’s ophthalmic importance is best understood through two complementary lenses: classical Ayurveda describes it as a chakshushya substance used in netra roga, while modern experimental work supports antioxidant, anti-inflammatory, retinal epithelial, and retinal microvascular rationales. Its role is supportive and adjunctive: Triphala and Triphala Ghrita may have a meaningful place in Ayurvedic eye care, but they do not replace diagnosis, monitoring, prescription drops, procedures, or emergency treatment by an ophthalmologist.
Triphala is the “three fruits” formulation of Haritaki (Terminalia chebula), Bibhitaki or Vibhitaki (Terminalia bellirica/Terminalia bellerica), and Amalaki (Emblica officinalis/Phyllanthus emblica), commonly prepared in equal parts as churna, decoction, or medicated ghee. In Ayurvedic eye care, its most defensible classical position is not merely as a digestive herb that incidentally benefits the eyes, but as an internal rasayana and a component of selected local netra-kriyakalpa practices when prepared and used appropriately.
Why Triphala Is Considered Chakshushya
In Ayurvedic language, chakshushya refers to substances and practices traditionally valued for the eyes and vision. Triphala fits this category because it combines cleansing, rasayana, and pitta-kapha balancing uses with a long-standing place in formulations for timira and netraroga. The National List of Essential AYUSH Medicines lists Triphala Ghrita with indications including Timira and Netraroga, and classical ophthalmic chapters include Triphala Ghrita in the management of eye disease.
This does not mean Triphala is a stand-alone cure for glaucoma, cataract, diabetic retinopathy, or retinal disease. It means Ayurveda places it within a wider eye-care framework that includes diet, bowel regulation, rasayana, medicated ghee, local procedures, seasonal discipline, and physician-guided treatment according to dosha, tissue involvement, disease stage, strength, age, and digestive capacity.
Mechanisms Relevant to Eye Health
Modern work on Triphala does not justify replacing ophthalmic treatment, but it does help explain why the formulation has remained important in Ayurvedic eye care. Its three fruits contain tannins and phenolic compounds such as gallic acid, ellagic acid, chebulagic acid, and chebulinic acid, which are relevant to oxidative stress, inflammatory signaling, tissue remodeling, and microvascular changes in ocular tissues.
Antioxidant and Lens Support
The retina is highly vulnerable to oxidative stress because of its oxygen demand, light exposure, and lipid-rich structure. Oxidative stress is also involved in cataract formation, diabetic retinal injury, glaucoma-related optic nerve damage, and age-related retinal degeneration. Triphala’s phenolic-rich profile supports its classical use as a protective rasayana for tissues exposed to oxidative load.
In experimental selenite-induced cataract models, Triphala protected lenses by improving antioxidant status and reducing lipid peroxidation. This supports the classical lens-support rationale, but it should not be interpreted as proof that Triphala can reverse human cataract or replace cataract surgery when surgery is indicated.
Retinal Pigment Epithelium and Fibrotic Remodeling
Retinal pigment epithelial cells are important for retinal integrity, and their abnormal migration and fibrotic transformation contribute to conditions such as proliferative vitreoretinopathy. In a human retinal pigment epithelial cell model, Triphala extracts and the Triphala constituents chebulagic acid and chebulinic acid reduced TGF-beta-induced epithelial-to-mesenchymal transition markers, cell migration, proliferation, and SMAD-3 phosphorylation.
This mechanism is relevant to retinal tissue remodeling, but it is not the same as proving an intraocular pressure-lowering effect in glaucoma. Claims that Triphala or gallic acid has been proven to reverse trabecular meshwork fibrosis in glaucoma should be treated cautiously unless supported by direct ophthalmic clinical evidence.
Retinal Microvascular Inflammation
Retinal microvascular inflammation is important in diabetic retinopathy and neovascular retinal disease. In retinal capillary endothelial cell models, Triphala-related compounds including chebulagic acid, chebulinic acid, and gallic acid inhibited TNF-alpha-induced pro-inflammatory and pro-angiogenic responses, including changes linked with endothelial migration, tube formation, and inflammatory mediators.
This provides a plausible adjunctive rationale for considering Triphala in broader metabolic and vascular eye-care plans, especially where pitta, rakta, kapha, and metabolic dysregulation are involved. It does not replace retinal screening, diabetic control, laser treatment, anti-VEGF injections, or other ophthalmologist-directed care.
Glaucoma and Optic-Nerve Care
Glaucoma is a progressive optic-nerve disease in which intraocular pressure, aqueous humour drainage, optic-nerve vulnerability, and vascular factors may all be relevant. Standard glaucoma care aims to lower intraocular pressure through prescription drops, laser, surgery, or other ophthalmic interventions. Triphala may be considered only as a supportive Ayurvedic measure under professional supervision, not as a substitute for glaucoma medicines.
For a person already diagnosed with glaucoma or ocular hypertension, the most important eye-saving actions are regular intraocular pressure checks, optic-nerve evaluation, visual-field monitoring, and adherence to prescribed treatment. Ayurvedic support may focus on rasayana, bowel regularity, inflammation reduction, sleep, diet, and safe physician-guided preparations, but prescription drops should never be stopped without the treating ophthalmologist’s agreement.
Classical Forms for Eye Care
Ayurvedic ophthalmology distinguishes internal formulations from local procedures. Triphala churna, Triphala decoction, and Triphala Ghrita are not interchangeable, and home preparation is not the same as a sterile clinical ophthalmic product. The eye is delicate; particles, contamination, wrong concentration, or improper handling can irritate the ocular surface and increase risk.
Triphala Jala or Triphala Kwatha for External Cleansing
Triphala water or decoction is traditionally used for external cleansing around the eyes and in physician-guided ophthalmic practice. A cautious household approach is to use freshly prepared, well-filtered Triphala water only for external cleansing around closed eyelids, not as a homemade drop placed into the open eye. Any preparation that is cloudy, gritty, fermented, old, or insufficiently filtered should be discarded.
A traditional-style preparation may involve soaking or gently decocting Triphala powder in clean water, allowing sediment to settle, and filtering repeatedly through a very fine sterile filter or cloth. Even then, household Triphala water should not be treated as a sterile eye drop. Burning, pain, increased redness, discharge, light sensitivity, blurred vision, or foreign-body sensation after use should be treated as a reason to stop and seek eye care.
Triphala Ghritam for Internal Use
Triphala Ghritam is a classical medicated ghee preparation in which Triphala is processed into ghee for internal rasayana use. The National List of Essential AYUSH Medicines lists Triphala Ghrita with indications including Timira and Netraroga, and gives an adult dose range of 10–15 g. In practice, dose and timing should be individualized by an Ayurvedic practitioner according to digestive strength, bowel tendency, metabolic status, age, and the nature of the eye condition.
Internal Triphala Ghritam is especially aligned with the Ayurvedic idea that the eyes require unctuous nourishment, pitta regulation, and rasayana support. It is not appropriate for everyone in the same dose. People with weak digestion, active nausea, loose stools, marked kapha accumulation, gallbladder or lipid-metabolism concerns, or those on complex medical treatment should use it only with qualified guidance.
Netra Tarpana
Netra Tarpana is a clinical Ayurvedic procedure in which medicated ghee is retained over the closed or gently opened eyes within a ring-like boundary for a defined period. Triphala Ghrita and other ghrita preparations may be selected according to the condition, dosha pattern, and practitioner assessment. This is not a home eye-bath; it requires clinical hygiene, correct medicine selection, correct duration, and post-procedure care.
Netra Tarpana is commonly considered for dry eye, ocular fatigue, vata-pitta irritation, and selected chronic ocular-surface complaints after proper examination. In an open-label comparative clinical trial on Shushkakshipaka correlated with dry eye syndrome, Triphala Ghrita Tarpana and Goghrita Manda Tarpana were used in a short supervised course and produced improvement in dry-eye symptoms and signs. This supports clinical use in dry-eye contexts, but it does not establish Netra Tarpana as treatment for all retinal, corneal, glaucomatous, or cataract conditions.
Dosage and Application Guide
The following guide is educational and conservative. Eye disease should be diagnosed first, and any internal or local Ayurvedic treatment should be matched to the patient rather than copied from a generic protocol.
| Application | Preparation | Usual Method | Frequency | Best-Fit Use | Important Safety Note |
|---|---|---|---|---|---|
| Internal rasayana support | Triphala churna, tablet, or extract | Practitioner-selected dose according to digestion and bowel tendency | Usually once daily or as prescribed | General metabolic, bowel, and rasayana support in eye-care plans | Avoid excessive dosing that causes loose stools, dehydration, or weakness |
| Classical eye-support ghrita | Triphala Ghritam | Classical/official adult references include 10–15 g, individualized in practice | As directed by an Ayurvedic practitioner | Timira, Netraroga, ocular fatigue, dry or degenerative tendencies where ghrita is suitable | Use cautiously in poor digestion, kapha excess, loose stools, or lipid/gallbladder concerns |
| External cleansing | Fresh Triphala Jala or Kwatha | External cleansing around closed eyelids only in household use | Occasional or short-term, not continuous unsupervised use | Eye fatigue, mild external irritation tendency, traditional cleansing support | Do not place homemade, non-sterile, or particle-containing liquid into the open eye |
| Clinical ocular procedure | Netra Tarpana with Triphala Ghrita or selected ghrita | Medicated ghee retained over the eyes in a clinical setting | Short supervised course, commonly several consecutive sessions | Dry eye, ocular fatigue, vata-pitta ocular-surface complaints | Requires trained practitioner, clean setting, correct indication, and post-procedure care |
| Glaucoma adjunct | Internal rasayana and physician-guided support | Only alongside ophthalmologist-directed care | Based on eye-pressure monitoring and medical plan | Supportive care for constitution, inflammation, sleep, bowel regulation, and tissue resilience | Never stop glaucoma drops or delay pressure-lowering treatment |
| Diabetic eye-care adjunct | Internal Triphala-based plan when suitable | Used with glucose control, retinal screening, and medical care | As prescribed | Metabolic and vascular support within an integrated plan | Does not replace retinal examination, laser, injections, or diabetic treatment |
Practical Ayurvedic Use Cases
For eye strain and dryness, Triphala is most appropriately considered as part of a broader plan that includes sleep correction, screen breaks, bowel regularity, adequate hydration, suitable fats, pitta-calming diet, and physician-guided ghrita where indicated. External Triphala preparations should be kept conservative and hygienic, while Netra Tarpana should be reserved for trained clinical settings.
For cataract tendency, Triphala’s classical and experimental rationale is antioxidant and rasayana support, not cataract reversal. A person with cloudy vision, glare, halos, or reduced night driving ability should have cataract assessment and follow the ophthalmologist’s advice on timing of surgery. Triphala Ghritam may be used as supportive Ayurveda when digestion, constitution, and medical status permit.
For diabetic retinopathy risk, Triphala may be considered only as an adjunct in a plan centered on blood-glucose control, blood-pressure control, lipid management, regular dilated retinal examinations, and timely retinal treatment. Its relevance is strongest as systemic rasayana and inflammatory-metabolic support, not as a replacement for diabetic eye care.
For glaucoma, Triphala should be framed even more cautiously. Glaucoma can progress silently and cause irreversible vision loss. Ayurvedic care may support the patient’s constitution and tissue resilience, but intraocular pressure and optic-nerve status must be monitored medically, and prescribed drops or procedures should continue unless the ophthalmologist changes them.
For related evidence-based herbal reviews, see our comprehensive guide on Triphala’s full pharmacological profile, our discussion of Nasyakarma for eye and neurological conditions, and Manjistha for vascular and eye support.
Safety and When to Seek Care
Glaucoma, cataract, diabetic retinopathy, retinal disease, corneal ulcer, eye injury, and sudden visual symptoms require assessment by a qualified ophthalmologist or healthcare provider. Ayurvedic treatments described here are adjunctive and should be used with guidance from a qualified Ayurvedic practitioner, especially when the preparation is internal ghrita or any local eye procedure. Never discontinue glaucoma drops, diabetic eye treatment, steroid drops, antibiotics, or other prescribed eye medicines without medical approval. Sudden vision loss, eye pain, halos around lights, severe redness, pus-like discharge, light sensitivity, new floaters, flashes, curtain-like shadow, or trauma to the eye requires urgent ophthalmological evaluation.
References
- Journals (journals.plos.org)
- Chebulagic acid Chebulinic acid and Gallic acid, the active principles of Triphala, inhibit TNFα induced pro-angiogenic and pro-inflammatory activities in retinal capillary endothelial cells by inhibiting p38, ERK and NFkB phosphorylation (2018), PubMed
- Evaluation of anticataract potential of Triphala in selenite-induced cataract: In vitro and in vivo studies (2010), PubMed
- Role of Oxidative Stress in Retinal Disease and the Early Intervention Strategies: A Review (2022), PubMed Central
- Upayushsociety (upayushsociety.com)
- Easyayurveda (easyayurveda.com)
- Efficacy of Triphala Ghrita and Goghrita Manda Tarpana in the management of Shushkakshipaka w.s.r. to dry eye syndrome: An open labelled randomized comparative clinical trial (2020), PubMed
- NCBI
- Mayoclinic (mayoclinic.org)
- My (my.clevelandclinic.org)
- Iovs (iovs.arvojournals.org)
- Sciencedirect (sciencedirect.com)
- Sciencedirect (sciencedirect.com)
- Sciencedirect (sciencedirect.com)
- LWW Journals
The IOVS 2022 paper on gallic acid and trabecular meshwork fibrosis is what got my attention too. My father has open-angle glaucoma and his ophthalmologist is skeptical of adjunct approaches, but that kind of mechanistic data is harder to dismiss than anecdote. Did the review cover any data on IOP reduction in human trials specifically? ❤️
Curious whether the review addresses any Pitta-eye connections — I’ve seen the idea that Pitta aggravation accelerates retinal degeneration, and Triphala’s Haritaki component is supposed to pacify Pitta. Does the article go into whether constitution-based dosing was used in any of the studies?
aragvadha pod pulp for constipation is gentle and predictable. unlike senna it doesn’t cause cramping.
Worth noting that the same RCT-evidence criticism could be leveled at a lot of ophthalmic supplements, including many Western ones that get recommended routinely. The gallic acid trabecular meshwork data here is at least mechanistically grounded — that’s more than we get from some widely used nutraceuticals for macular support.
That’s a fair point about thin evidence generally, but this post is specifically about Triphala and eyes, not Vasa — different mechanisms, different evidence base. The retinal oxidative stress angle for Triphala actually has a few decent human studies worth looking at before drawing the same conclusion.
The article does mention gallic acid and ellagic acid as key actives — both of which are well-studied antioxidants. Seems like that safety-profile gap (who should avoid it, when) is worth the author addressing in a follow-up, because people with specific conditions will definitely try this based on the review.
The review covers a lot of ground on mechanism but I agree some contraindication clarity would help. Even something like a brief note on when to consult before starting Triphala eye washes — people with compromised corneas, for instance — would make this more complete. tbh
That’s what I appreciated too — the breakdown of gallic acid, ellagic acid, and chebulinic acid rather than just saying ‘Triphala is good for eyes.’ Understanding that gallic acid inhibits trabecular meshwork fibrosis is a completely different level of explanation than most Ayurveda content gives you. 💯
Wondering about the Triphala preparation details in the studies cited — was it primarily churna in water, or ghrita-based? I’ve read that the fat-soluble compounds may absorb differently and the ophthalmic effects could depend on which preparation was used.
triphala for eyes is interesting but glaucoma is serious, so i like that it doesnt sound like a replacement for drops
Good one.
vasa (Adhatoda) syrup for my recurrent bronchitis doctor prescribed it alongside azithromycin and the recovery was faster than previous episodes.
Will try!
The section on Triphala eye wash (Netra Tarpana concept) was interesting but I’d want to know more about sterility concerns with home preparation. Has anyone here actually done the cooled decoction wash and had it assessed by an eye doctor? ✨
On the constitution question — I noticed the studies cited didn’t seem to account for Prakriti at all, which is a pretty significant omission from a classical Ayurvedic standpoint. Triphala is generally tridoshic but the proportions of the three fruits are sometimes adjusted for Pitta types. Did anyone see dosing stratification mentioned anywhere in the review?
Useful info. 🙌
the retina evidence part needs more numbers. was it animal data, small trial, or just traditional use
The 2022 IOVS study referenced here is the one I’d been looking for — I’d seen it cited secondhand but never in the context of Ayurvedic medicine. Linking gallic acid specifically to trabecular meshwork health rather than just general antioxidant effects makes this clinically more interesting than the usual write-ups.
I found the section on gallic acid inhibiting trabecular meshwork fibrosis really eye-opening.
The loose stool effect is worth flagging in the context of long-term Triphala use for eye health too — some people take fairly high doses expecting ocular benefits and don’t realize the laxative action compounds over time. A maintenance dose note alongside the evidence summary would be useful.
Off topic question but is Triphala safe for long-term daily use?
@Suresh agreed — the mechanistic breakdown here is exactly what convinces me to take Ayurvedic research more seriously. Chebulinic acid inhibiting retinal lipid peroxidation is the kind of specific claim that can actually be tested and reproduced, which is different from vague adaptogen language.
Doing this.
Related question on standardization — the studies reviewed presumably used specific extract concentrations, but off-the-shelf Triphala churna or tablets vary a lot in gallic acid content. Did the review mention what potency or ratio was used in the trials showing retinal protective effects?
My optometrist was surprised when I mentioned the IOVS research on Triphala and glaucoma — said she hadn’t seen it come through her journals. Ended up sharing the link with her. It’s interesting how ophthalmology and Ayurvedic research don’t seem to cross-pollinate much even when the evidence is published in mainstream journals.
@Sneha that’s a really practical gap to flag — the review focuses on evidence but doesn’t map out who the population of safe users actually is. Pregnancy, immunosuppressant use, people with very low IOP to begin with — these are all cases where even a generally safe herb like Triphala needs a qualifier.
@Sneha yeah pregnancy cautions matter, but this triphala eye post is more about glaucoma and retina. still, safety section should mention who should skip it
@Sneha the point about safety gaps in the review stands regardless of individual circumstance — even beyond pregnancy, the article doesn’t clearly state who should check with a physician before using Triphala eye wash versus internal use. Those are two very different routes of administration with different risk profiles.
Triphala taken at night is actually the classical recommendation for eye health benefits too — something about Pitta being most active at midnight and the antioxidant action working while the eyes are at rest. I’ve been doing 1 tsp in warm water before bed for about four months and my dry eye symptoms have noticeably reduced, for whatever that’s worth.
The IOP reduction numbers from the 2022 trial seem promising for adjunct use.
The standardization problem applies to Triphala too — the gallic acid content varies significantly between suppliers and even between batches. If the mechanism the IOVS paper describes depends on gallic acid concentration, using an unstandardized churna is a bit of a shot in the dark. tbh
How does Triphala Ghritam compare to regular fish oil for retinal support?
@Kiran that’s exactly it — the ellagic acid section especially. Most articles just say ‘antioxidant’ and leave it there, but explaining that ellagic acid specifically modulates VEGF signaling in retinal tissue gives you something concrete to discuss with a specialist.
The retinal oxidative stress discussion is thorough but I’d have liked more on the difference between internal Triphala use and topical eye wash in terms of which route actually delivers enough active compound to the posterior segment. Those are very different pharmacokinetic questions.
The gallic acid mechanism explanation was the highlight for me — most Ayurveda content either goes fully classical (rasas, gunas) or fully vague-science. Actually citing a named compound acting on a named tissue pathway is what makes this review stand out from the usual content.
I tried the eye wash recipe and noticed less redness after a long day at the computer.
Makes sense.
Same here.
The antioxidant data linking Amalaki to lens protection makes sense given its vitamin C content.
My uncle’s ophthalmologist recently mentioned that oxidative stress is now considered a primary driver in both glaucoma and diabetic retinopathy — which is exactly the space where Triphala’s antioxidant profile seems relevant. Has anyone here tried discussing the IOVS findings directly with their eye doctor?
The chemistry section here is genuinely well done — chebulinic acid inhibiting retinal lipid peroxidation is the kind of specificity I was hoping to find. It’s not just ‘ancient wisdom’; there’s an actual molecular explanation for why Haritaki’s contribution to Triphala might matter for eye health specifically.
Are there any known interactions between Triphala supplements and common blood pressure meds?
The historical references from Charaka Samhita add weight to the modern findings.
The trabecular meshwork angle is what got my attention here. My father has open-angle glaucoma and his ophthalmologist has never mentioned anything about adjunct support. Has anyone actually brought up Triphala research like the IOVS study with their eye specialist?
Sterile preparation for eye drops is essential to avoid corneal irritation.
Seeing diabetic retinopathy markers improve with oral Triphala encourages further research.
The gallic acid data from that IOVS paper is compelling, but I’d push back slightly on how it’s framed — in vitro inhibition of fibrosis is a long way from demonstrated IOP reduction in patients. Curious whether there are any human trials in the pipeline following those findings.